TShmt2-Shmt2SGOC510-1-C KGTT mem PD-L1PD-L1BCAT1BCAABCAT1BCAABCAAsmTOR T reg T eff T eff TCRT reg GRagA/B Rheb1/2T reg mTORC1T reg T(ICOS)CTLA4B16RagAT reg CD8 + TB TGls1DCsTmGlu5RTCRTmGlu1RMEK-ERK1/2mGlu5RIL-2IFN-BDCskainateB -23-1IDO-1IDO-1 TIDO-1T IDO-1IDOTTTTCRT reg NK pDCsIDOTDCsTDCsIDOTDCsTMDSCsCD8 + TMDSCsCD8 + TCD8 + T IFN-NK(TAMS)TAMSNKT CD8 + TTIFN--X C Slc3a2 Slc7a11TMDSCsTTDCsGSH MC38OXPHOSCD8 + TTILsTILSMC38TCAT 2(Nrf)2/KelchECH(Keap)1Keap1 PTMs5 Figure 5
The study participants took liposomal glutathione for 12 weeks and showed significant improvements in liver enzymes, liver function tests, and liver steatosis (fatty liver)
In fact, this concept of using LC supplementation to provoke a latent metabolic phenotype has been explored in septic shock patients [17]
Recent Phase 3 data showed average weight reduction exceeding 28% in some participant groups after extended treatment periods
Results from the first Phase III trial in obesity and overweight investigating the GIPR/GLP-1R co-agonist tirzepatide, which is currently approved for the treatment of type 2 diabetes and has resulted in marked body-weight reductions in type 2 diabetes [5, 43,44,45,46], were published in 2022 [28]
